Buck Wealth Strategies LLC Buys 13,652 Shares of Exelixis, Inc. $EXEL

Buck Wealth Strategies LLC boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 61.1% during the fourth quarter, HoldingsChannel reports. The fund owned 36,005 shares of the biotechnology company’s stock after buying an additional 13,652 shares during the quarter. Buck Wealth Strategies LLC’s holdings in Exelixis were worth $1,578,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in EXEL. Richardson Financial Services Inc. lifted its holdings in Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 292 shares during the last quarter. Anchor Investment Management LLC grew its position in shares of Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. Root Financial Partners LLC purchased a new position in shares of Exelixis during the third quarter worth about $28,000. Activest Wealth Management purchased a new position in Exelixis in the fourth quarter worth $32,000. Finally, Northwestern Mutual Wealth Management Co. grew its position in Exelixis by 1,380.4% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 773 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Stifel Nicolaus upped their price target on shares of Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research report on Wednesday. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday. Royal Bank Of Canada decreased their target price on shares of Exelixis from $46.00 to $43.00 and set a “sector perform” rating for the company in a research note on Monday, March 2nd. Finally, Morgan Stanley raised their target price on shares of Exelixis from $49.00 to $50.00 and gave the company an “equal weight” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $47.83.

Insiders Place Their Bets

In other Exelixis news, Director Maria C. Freire sold 20,634 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $46.00, for a total value of $949,164.00. Following the sale, the director owned 100,819 shares in the company, valued at $4,637,674. The trade was a 16.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack L. Wyszomierski sold 99,574 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $4,382,251.74. Following the completion of the sale, the director owned 279,942 shares in the company, valued at approximately $12,320,247.42. The trade was a 26.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 451,195 shares of company stock worth $19,982,874. 2.60% of the stock is owned by corporate insiders.

Key Stories Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Exelixis reported solid Q1 results, with revenue of $610.8 million and earnings per share of $0.87, both ahead of expectations. The company also completed its prior buyback authorization and launched a new $750 million share repurchase program, which can support the stock by reducing share count. Article Title
• Positive Sentiment: Analysts turned more constructive, with HC Wainwright raising its price target to $56 and Morgan Stanley lifting its target to $50, signaling improved confidence in Exelixis’ outlook. Article Title Article Title
• Positive Sentiment: The company also announced upcoming investor conference appearances in May, which may help keep investor attention on its pipeline and strategy. Article Title
• Neutral Sentiment: Several directors disclosed stock sales on May 7, including George Poste, Maria C. Freire, and Mary C. Beckerle. Insider selling can create some near-term caution, but the transactions were disclosed and do not by themselves indicate a change in the business outlook. Article Title Article Title Article Title

Exelixis Stock Performance

EXEL opened at $48.16 on Friday. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $49.62. The firm’s fifty day moving average is $43.44 and its 200 day moving average is $42.97. The stock has a market cap of $12.11 billion, a price-to-earnings ratio of 16.00, a price-to-earnings-growth ratio of 0.99 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. During the same period in the previous year, the firm earned $0.55 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. On average, equities research analysts predict that Exelixis, Inc. will post 3.11 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.